Abstract
Abstract Objectives: We have identified potential biomarkers for gastric cancer using a cDNA bank on the basis of mRNA extracted from frozen specimens of gastric cancer tissue and adjacent normal gastric mucosa. We report currently available results. Methods: The study group comprised 227 patients in whom 5 or more years had elapsed since gastrectomy. The disease stage was IB in 29 patients, II in 66, III in 103, and IV in 29. Among the 139 patients who postoperatively received fluoropyrimidines, 97 with stage II or III disease were given adjuvant chemotherapy with S-1. A total 104 genes were selected on the basis of the results of comprehensive DNA microarray analysis, extraction from serial analysis of gene expression (SAGE) libraries, and preclinical and other studies of potential targets for molecular-targeted therapy. The relative expression levels of these genes in gastric cancer tissue and adjacent normal mucosa from each patient were measured by a quantitative polymerase chain reaction assay using the cDNA bank described above, and the relations between clinicopathological factors and outcomes were examined. Results: In patients who underwent gastrectomy, high expression of matrix metalloproteinase-9 (MMP9), insulin-like growth factor receptor 1 (IGF-R1), and apolipoprotein E (APOE) genes were associated with significantly worse outcomes. In patients with stage II or III disease who received adjuvant chemotherapy with S-1, high expression of IGF-R1, thymidylate synthase (TS), and regenerating IV (Reg IV) genes were associated with significantly worse outcomes. Conclusions: MMP9, IGFR-1, and APOE gene expression levels were suggested to be useful prognostic factors in patients who underwent gastrectomy for gastric cancer. In patients with stage II or III disease who received adjuvant chemotherapy with S-1, IGF-1R, TS, and Reg IV gene expression levels were suggested to be useful prognostic factors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4489. doi:1538-7445.AM2012-4489
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
